Eight Months and $30,000 Before Subject Enrollment: The Real Price of Another Site

Enrollment is behind, so the plan is to add clinical research sites. It feels like progress. It looks like a fix. It’s also the most expensive way to stay exactly where you are.

Adding sites is a rational instinct. When the timeline slips and the board wants a number, expanding the network is the fastest lever available.

But the instinct rests on an assumption: more sites means more patients, faster. The data disagrees.

What another trial site really costs

Adding a clinical trial site carries costs most plans miscalculate:

• Eight months before it helps, contracts, ethics review, training, and site initiation push the average time to open a new site to nearly eight months, before it enrolls a single patient.
• $20,000 to $30,000 to start, then about $1,500 a month to keep open. That spend starts before the site produces a single enrollment, and it compounds every month the site underperforms.

More sites only help when capacity is the constraint

More sites only help when the shortfall is a capacity problem. If the constraint is eligibility criteria or market fit, a bigger network spreads the same problem across a bigger budget.

So why do teams keep adding sites? Because it’s the one move that looks decisive in a board meeting. Diagnosing the protocol looks like hesitation.

Adding sites looks like action, but it costs the patient too. A wider network does not reach more eligible people when the eligibility window is narrow. It turns more willing patients away at screening. The people who wanted in were never the problem. The criteria were.

Diagnose the cause before you commit the budget 

Before you add a site, answer why enrollment is behind. It usually traces to one of three things: patient availability, protocol design, or site strategy. Only one of those is a site problem. A wider network cannot answer the other two.

An MFT surveys real patients against your eligibility criteria before a single site opens. You see how many people your protocol qualifies while the plan is still cheap to change, so a narrow criterion surfaces as a number on a screen, not as six months of underperforming sites.

What recent data shows 

In Antidote’s GLP-1 switch-study Market Feasibility Test (2025):

• The early signals looked strong. 35% of visitors converted on the landing page, alongside a 3% click-through rate.
• Then the criteria hit. Once treatment-history requirements applied, only 3% qualified.
• The fix was the eligibility window, not the network. The team tested alternative windows before committing to more sites.

Adding sites is not the risk.

The risk is committing the budget and the timeline to more sites before you know whether site count was ever the problem.